These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 23338488)

  • 1. Ablative margin states by magnetic resonance imaging with ferucarbotran in radiofrequency ablation for hepatocellular carcinoma can predict local tumor progression.
    Koda M; Tokunaga S; Miyoshi K; Kishina M; Fujise Y; Kato J; Matono T; Murawaki Y; Kakite S; Yamashita E
    J Gastroenterol; 2013 Nov; 48(11):1283-92. PubMed ID: 23338488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical usefulness of the ablative margin assessed by magnetic resonance imaging with Gd-EOB-DTPA for radiofrequency ablation of hepatocellular carcinoma.
    Koda M; Tokunaga S; Okamoto T; Hodozuka M; Miyoshi K; Kishina M; Fujise Y; Kato J; Matono T; Sugihara T; Oyama K; Hosho K; Okano J; Murawaki Y; Kakite S; Yamashita E
    J Hepatol; 2015 Dec; 63(6):1360-7. PubMed ID: 26232269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of ablative margin by MRI with ferucarbotran in radiofrequency ablation for liver cancer: comparison with enhanced CT.
    Tokunaga S; Koda M; Matono T; Sugihara T; Nagahara T; Ueki M; Murawaki Y; Kakite S; Yamashita E
    Br J Radiol; 2012 Jun; 85(1014):745-52. PubMed ID: 21385915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of ablative margin after radiofrequency ablation for hepatocellular carcinoma; comparison between magnetic resonance imaging with ferucarbotran and enhanced CT with iodized oil deposition.
    Koda M; Tokunaga S; Fujise Y; Kato J; Matono T; Sugihara T; Nagahara T; Ueki M; Murawaki Y; Kakite S; Yamashita E
    Eur J Radiol; 2012 Jul; 81(7):1400-4. PubMed ID: 21440397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging evaluation of ablative margin and index tumor immediately after radiofrequency ablation for hepatocellular carcinoma: comparison between multidetector-row CT and MR imaging.
    Kim SM; Shin SS; Lee BC; Kim JW; Heo SH; Lim HS; Jeong YY
    Abdom Radiol (NY); 2017 Oct; 42(10):2527-2537. PubMed ID: 28409202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety margin of radiofrequency ablation for hepatocellular carcinoma: a prospective study using magnetic resonance imaging with superparamagnetic iron oxide.
    Fukuda K; Mori K; Hasegawa N; Nasu K; Ishige K; Okamoto Y; Shiigai M; Abei M; Minami M; Hyodo I
    Jpn J Radiol; 2019 Jul; 37(7):555-563. PubMed ID: 31102138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of ablative margin by unenhanced magnetic resonance imaging after radiofrequency ablation for hepatocellular carcinoma.
    Koda M; Tokunaga S; Miyoshi K; Kishina M; Fujise Y; Kato J; Matono T; Okamoto K; Murawaki Y; Kakite S
    Eur J Radiol; 2012 Oct; 81(10):2730-6. PubMed ID: 22137612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of radiofrequency ablation margin by MRI-MRI image fusion in hepatocellular carcinoma.
    Wang XL; Li K; Su ZZ; Huang ZP; Wang P; Zheng RQ
    World J Gastroenterol; 2015 May; 21(17):5345-51. PubMed ID: 25954109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of Local Tumor Progression after Radiofrequency Ablation (RFA) of Hepatocellular Carcinoma by Assessment of Ablative Margin Using Pre-RFA MRI and Post-RFA CT Registration.
    Yoon JH; Lee JM; Klotz E; Woo H; Yu MH; Joo I; Lee ES; Han JK
    Korean J Radiol; 2018; 19(6):1053-1065. PubMed ID: 30386137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The minimal ablative margin of radiofrequency ablation of hepatocellular carcinoma (> 2 and < 5 cm) needed to prevent local tumor progression: 3D quantitative assessment using CT image fusion.
    Kim YS; Lee WJ; Rhim H; Lim HK; Choi D; Lee JY
    AJR Am J Roentgenol; 2010 Sep; 195(3):758-65. PubMed ID: 20729457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3D fusion is superior to 2D point-to-point contrast-enhanced US to evaluate the ablative margin after RFA for hepatocellular carcinoma.
    Long H; Zhou X; Zhang X; Ye J; Huang T; Cong L; Xie X; Huang G
    Eur Radiol; 2024 Feb; 34(2):1247-1257. PubMed ID: 37572191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rate of local tumor progression following radiofrequency ablation of pathologically early hepatocellular carcinoma.
    Hao Y; Numata K; Ishii T; Fukuda H; Maeda S; Nakano M; Tanaka K
    World J Gastroenterol; 2017 May; 23(17):3111-3121. PubMed ID: 28533668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-hypervascular hepatobiliary phase hypointense nodules on gadoxetic acid-enhanced MRI: risk of HCC recurrence after radiofrequency ablation.
    Lee DH; Lee JM; Lee JY; Kim SH; Kim JH; Yoon JH; Kim YJ; Lee JH; Yu SJ; Han JK; Choi BI
    J Hepatol; 2015 May; 62(5):1122-30. PubMed ID: 25529623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrahepatic distant recurrence following complete radiofrequency ablation of small hepatocellular carcinoma: risk factors and early MRI evaluation.
    Sheng RF; Zeng MS; Ren ZG; Ye SL; Zhang L; Chen CZ
    Hepatobiliary Pancreat Dis Int; 2015 Dec; 14(6):603-12. PubMed ID: 26663008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Percutaneous radiofrequency ablation therapy for hepatocellular carcinoma: a proposed new grading system for the ablative margin and prediction of local tumor progression and its validation.
    Nishikawa H; Inuzuka T; Takeda H; Nakajima J; Sakamoto A; Henmi S; Matsuda F; Eso Y; Ishikawa T; Saito S; Kita R; Kimura T; Osaki Y
    J Gastroenterol; 2011 Dec; 46(12):1418-26. PubMed ID: 21845378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiofrequency ablation of hepatocellular carcinoma sized > 3 and ≤ 5 cm: is ablative margin of more than 1 cm justified?
    Ke S; Ding XM; Qian XJ; Zhou YM; Cao BX; Gao K; Sun WB
    World J Gastroenterol; 2013 Nov; 19(42):7389-98. PubMed ID: 24259969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of Nonrigid Registration of Pre-Procedure MR with Post-Procedure CT After Radiofrequency Ablation for Hepatocellular Carcinoma.
    Park J; Lee JM; Lee DH; Joo I; Yoon JH; Park JY; Klotz E
    Cardiovasc Intervent Radiol; 2017 Jun; 40(6):873-883. PubMed ID: 28091728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative evaluation of three-dimensional Gd-EOB-DTPA-enhanced MR fusion imaging with CT fusion imaging in the assessment of treatment effect of radiofrequency ablation of hepatocellular carcinoma.
    Makino Y; Imai Y; Igura T; Hori M; Fukuda K; Sawai Y; Kogita S; Fujita N; Takehara T; Murakami T
    Abdom Imaging; 2015 Jan; 40(1):102-11. PubMed ID: 25052767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiofrequency ablation of the liver: determination of ablative margin at MR imaging with impaired clearance of ferucarbotran--feasibility study.
    Mori K; Fukuda K; Asaoka H; Ueda T; Kunimatsu A; Okamoto Y; Nasu K; Fukunaga K; Morishita Y; Minami M
    Radiology; 2009 May; 251(2):557-65. PubMed ID: 19251941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin.
    Nakazawa T; Kokubu S; Shibuya A; Ono K; Watanabe M; Hidaka H; Tsuchihashi T; Saigenji K
    AJR Am J Roentgenol; 2007 Feb; 188(2):480-8. PubMed ID: 17242258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.